Raymond James Financial Inc Apellis Pharmaceuticals, Inc. Transaction History
Raymond James Financial Inc
- $258 Billion
- Q1 2025
A detailed history of Raymond James Financial Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 51,978 shares of APLS stock, worth $873,230. This represents 0.0% of its overall portfolio holdings.
Number of Shares
51,978
Previous 49,015
6.05%
Holding current value
$873,230
Previous $1.56 Million
27.37%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding APLS
# of Institutions
295Shares Held
124MCall Options Held
921KPut Options Held
761K-
Wellington Management Group LLP Boston, MA12.3MShares$207 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$205 Million4.32% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$200 Million20.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$170 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$162 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $1.85B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...